WO1997036616A2 - Agent anti-tumoral - Google Patents
Agent anti-tumoral Download PDFInfo
- Publication number
- WO1997036616A2 WO1997036616A2 PCT/GB1997/000917 GB9700917W WO9736616A2 WO 1997036616 A2 WO1997036616 A2 WO 1997036616A2 GB 9700917 W GB9700917 W GB 9700917W WO 9736616 A2 WO9736616 A2 WO 9736616A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pdm
- moiety
- leu
- gly
- agent
- Prior art date
Links
- 0 **c(cc1)ccc1[N+]([O-])=O Chemical compound **c(cc1)ccc1[N+]([O-])=O 0.000 description 6
- CZGCEKJOLUNIFY-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1Cl)=O Chemical compound [O-][N+](c(cc1)ccc1Cl)=O CZGCEKJOLUNIFY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
Definitions
- This invention relates to an anti-tumor agent and is more particularly concerned with an anti-tumor agent utilising an active alkylating moiety selected from the class of compounds referred to as "nitrogen mustards", for example N,N-di(2-chloroethyl)-4-phenylenediamine (hereinafter sometimes referred to as "PDM”) and active analogues thereof.
- Nitrogen mustards are so called because of their ability to form cyclic onium salts in an analogous manner to the ability of mustard gas to form cyclic sulphonium salts. Nitrogen mustards have not previously found acceptability for use as anti-tumor agents because of their high systemic toxicity and short half-life.
- an anti-tumor agent comprising a macromolecular carrier moiety; an active alkylating moiety which is a nitrogen mustard; and a stabilising moiety linking the active alkylating moiety with the carrier moiety, said stabilising moiety being an oligopeptide which is capable of being cleaved by a tumour-associated protease and which stabilises the active alkylating moiety by electron withdrawal and/or by inducing formation of aggregates.
- the active alkylating moiety is stabilised so that, instead of having a free-form half- life of typically about 1 1 minutes, when linked to the stabilising and carrier moieties as in the present invention, it has a typical half-life of about 1 1 hours.
- the stabilising moiety has been cleaved in use by the tumour-associated protease, the released alkylating moiety is very effective in killing the targeted tumor cells whilst degrading rapidly to reduce systemic toxicity.
- the oligopeptide is preferably one which can be cleaved by a
- the oligopeptide is preferably a tetra-, penta- or hexa-peptide, more preferably a tetra- or penta-peptide, and most preferably a tetra-peptide.
- the peptides in the oligopeptide will be identified by reference to their positions relative to the active alkylating moiety, with the peptide nearest the active alkylating moiety being designated as peptide 1 , the adjacent peptide being designated as peptide 2, and so on.
- Peptide 1 is preferably Leu, although Gly may be possible.
- Peptide 2 is preferably Ala, particularly when peptide 1 is Leu, although Leu may be possible if peptide 1 is Gly.
- Peptide 3 is preferably Phe or Leu, particularly when peptide 1 is Leu and peptide 2 is Ala; and most preferably petide 3 is Phe, particularly when peptide 1 is Leu and peptide 2 is Ala.
- Peptide 4 is preferably Gly or Ala and most preferably is Gly.
- oligopeptide terminates with, or consists of, the tetra-peptide, Gly-Phe-Ala-Leu, although it is considered that oligopeptides terminating with, or consisting of, the tetra-peptide Gly- Phe-Leu-Gly or Ala-Leu-Ala-Leu may be used.
- the macromolecular carrier moiety is preferably hydrophilic and is most preferably a polymeric moiety such as poly-[N 5 -(2-hydroxyethyl)-L- glutamine] (PHEG) or any other per se known macromolecular moiety, for example as described in EP-A-0187547.
- PHEG poly-[N 5 -(2-hydroxyethyl)-L- glutamine]
- the active alkylating moiety is a nitrogen mustard, for example N,N-di(2- chloroethyl)-4-phenylenediamine (PDM) which may be produced using the following reaction scheme:-
- the PDM may be replaced by any active analogous mustard, for example:-
- R 1 and R 2 are independently selected from
- the anti-tumor agent of the present invention can be produced by first coupling the nitrogen mustard with an oligopeptide in accordance with the reaction scheme below (given, by way of example, for PDM):-
- R is an oligopeptide moiety as described above.
- the resultant low molecular weight peptidyl-PDM derivative may then be coupled to a 4-n ⁇ trophenyl chloroformate activated poly-[N 5 -(2- hydroxyethyl)-L-glutam ⁇ ne] (PHEG) which can be produced in
- poly-L-glutamic acid derivatives can be produced in a similar way using other aminoalkanols, eg aminopropanol, in place of the
- the anti-tumor agent may be administered intravenously, intraperitoneally or intra-arterially.
- Poly-[N 5 -(2-hydroxyethyl)-L-glutamine] (PHEG) was used in this Example as the macromolecular carrier because it is non toxic, non immunogenic and possesses primary hydroxyl side groups which can be easily converted into reactive carbonate esters by reaction with a
- chloroformate-type compound eg 4-nitrophenyl chloroformate
- this synthetic polyaminoacid is a good substrate for lysosomal enzymes, preventing unwanted accumulation of the polymer in the body.
- glycine was used because this yields a water-soluble, low molecular weight Gly-PDM derivative.
- Gly-Leu-Phe-PDM and Gly-Phe-Ala-leu PDM were also prepared.
- amine-containing peptide-PDM moieties were coupled to the chloroformate activated carrier.
- the hydrolytic stability of PDM, water-soluble Gly-PDM and the oligopeptide-PDM derivatives was investigated in buffers of lysosomal and physiological pH. Dynamic laser light scattering provided insight in the obtained results. Furthermore, the degradation in presence of tritosomes, cathepsin A and collagenase type IV was studied.
- aminoacids and peptides were obtained from Bachem Chem Co. (Bubendorf Switzerland), 4-nitrophenyl chloroformate was obtained from Merck (Darmstadt, Germany).
- Collagenase type IV was obtained from Sigma Chem. Co. (St. Louis, Missouri, U.S.A). All other chemicals were purchased from Acros (Beerse, Belgium).
- N-carboxyan hydride was prepared by reaction of ⁇ -benzyl-L- glutamine with diphosgene in ethylacetate.
- the NCA was crystallised twice from ethyl acetate/hexane.
- Poly-( ⁇ -benzyl-L-glutamine) (PBLG) was prepared by polymerisation of the respective NCA in
- PBLG was precipitated in excess methanol/ether (2/1 v/v), filtered and dried.
- Aminolysis with 2-aminomethanol in presence of 2-hydroxypyridine as a catalyst was carried out in DMF.
- PHEG was precipitated in excess ether/ethanol (4/1 v/v), filtered and dialyzed against water for 2 days. After freeze-drying, pure PHEG was obtained as a white powder.
- 3 mg of PDM or Gly-PDM were dissolved in 40 ml of buffer and at regular times samples were withdrawn and analyzed using RP-HPLC (column: Zorbax ODS C18 4.6mm x 150 mm flow : 1 ml/min injection volume : 20 ⁇ l).
- 0.51 mg Na 2 S 2 O 4 were simultaneously added to the incubation mixture to prevent oxidation of the mustard.
- the percentage of hydrolysis of the mustard was calculated by comparing the area under the curve (AUC) at a certain time to the AUC at the start oi the reaction.
- the retention times of PDM and Gly-PDM are 7.2 min, respectively 4.5 min.
- Collagenase IV from Clostridium histolytcum was dissolved in phosphate buffered saline (PBS) to poduce concentrations of 4.5 mg/ml, 1 mg/ml and 0.1 mg/ml.
- 1 mg PHEG-peptidylPDM conjugate was dissolved in 0.6 ml PBS, 0.4 ml of enzyme solution were added and the mixture was incubated at 37 °C.
- MCF7 wt cells were suspended in a solution of RPMI-medium (5% Fetal Calf Serum and 1 % L-glutamine) after removal rom their flasks with trypsin.
- the solution contained 10 4 cell/ml.
- the cells were added to flat-bottomed 96-welled plates and incubated for 24 hours.
- P-O-PDM PHEG-Gly-Phe-Ala-Leu-PDM
- Test example 1 was repeated with the exception that C26 cells were used instead of MCF7 wt cells. The results obtained are shown in Fig. 6 and in Table 4 below.
- Conditioned cell medium was prepared by collecting medium containing tumour-secreted proteases from A-375M cells ( containing approximately 750 x 10 4 cells in 10ml of DME-medium) after incubation of these cells in their flasks for 72 hours. This medium was used as such, without further dilution or purification.
- PDM 4mg PDM were dissolved in 2 ml of distilled water and the solution was filtered. A 100 ⁇ M stock solution of PDM in DME-medium was made up and further diluted to 50, 10, 1 and 0.1 ⁇ M. After removal of the medium, 100 ⁇ l of each solution together with 100 ⁇ l of FCM or CCM were added to the wells, and the plates were incubated for 72 hours.
- mice Female BALB/c mice (5-6 weeks old) were subcutaneously inoculated with 10 5 C26 murine colorectal carcinoma cells. When the tumours were palpable, groups of 5 animlas were treated in vivo on each of three consecutive days with either free PDM (2 or 5 mg/kg), P-O-PDM (2, 5 or 8 mg/kg related to the PDM component) or saline (as a control). The animals were weighed daily and tumour growth measured. Animals receiving free PDM (5 mg/kg) showed rapid weight loss and were put down after 4-6 days following treatment due to treatment-related toxicity. Animals treated with PDM (2 mg/kg) showed tumour growth identical with saline-treated control animals and they were put down after 10-12 days due to tumour burden.
- P-O-PDM 8mg/kg (17 17, 18, 18, 18.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97915567A EP0891191A1 (fr) | 1996-04-02 | 1997-04-01 | Agent anti-tumoral |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9606975.2A GB9606975D0 (en) | 1996-04-02 | 1996-04-02 | Anti-tumor agent |
GB9606975.2 | 1996-04-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997036616A2 true WO1997036616A2 (fr) | 1997-10-09 |
WO1997036616A3 WO1997036616A3 (fr) | 1997-11-06 |
Family
ID=10791505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/000917 WO1997036616A2 (fr) | 1996-04-02 | 1997-04-01 | Agent anti-tumoral |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0891191A1 (fr) |
GB (1) | GB9606975D0 (fr) |
WO (1) | WO1997036616A2 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000078791A2 (fr) * | 1999-06-17 | 2000-12-28 | Universiteit Gent | DERIVES FONCTIONNELS POLY-α-AMINO ACIDE UTILES POUR LA MODIFICATION DE MATIERES A ACTIVITE BIOLOGIQUE ET APPLICATION DE CES DERIVES |
WO2001018548A2 (fr) * | 1999-09-09 | 2001-03-15 | Dade Behring Marburg Gmbh | Groupes protecteurs pour marquage biologique |
WO2002034237A1 (fr) * | 2000-08-22 | 2002-05-02 | New River Pharmaceuticals, Inc. | Systemes de liberations d'agents actifs et procedes de protection et d'administration d'agents actifs |
EP1490090A2 (fr) * | 2002-02-22 | 2004-12-29 | New River Pharmaceuticals Inc. | Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs |
US7018654B2 (en) | 1999-03-05 | 2006-03-28 | New River Pharmaceuticals Inc. | Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US7338939B2 (en) | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
US7375082B2 (en) | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
US7375083B2 (en) | 2003-09-30 | 2008-05-20 | Shire Llc | Pharmaceutical compositions for prevention of overdose or abuse |
US7622441B2 (en) | 2002-02-22 | 2009-11-24 | Shire Llc | Sustained release pharmaceutical compounds to prevent abuse of controlled substances |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106397102A (zh) * | 2016-08-29 | 2017-02-15 | 山东同成医药股份有限公司 | 卤代烃产品及其密封保温增压式生产方法 |
CN106905191B (zh) * | 2017-03-05 | 2019-03-29 | 北京化工大学 | 一种含有羟肟酸基团的氮芥类化合物及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017471A (en) * | 1975-09-15 | 1977-04-12 | G. D. Searle & Co. | Immunological compounds |
EP0040506A2 (fr) * | 1980-05-21 | 1981-11-25 | Teijin Limited | Polymère réactif et procédé pour sa préparation |
EP0187547A2 (fr) * | 1985-01-04 | 1986-07-16 | Ceskoslovenska akademie ved | Médicaments synthétiques polymères |
-
1996
- 1996-04-02 GB GBGB9606975.2A patent/GB9606975D0/en active Pending
-
1997
- 1997-04-01 WO PCT/GB1997/000917 patent/WO1997036616A2/fr not_active Application Discontinuation
- 1997-04-01 EP EP97915567A patent/EP0891191A1/fr not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017471A (en) * | 1975-09-15 | 1977-04-12 | G. D. Searle & Co. | Immunological compounds |
EP0040506A2 (fr) * | 1980-05-21 | 1981-11-25 | Teijin Limited | Polymère réactif et procédé pour sa préparation |
EP0187547A2 (fr) * | 1985-01-04 | 1986-07-16 | Ceskoslovenska akademie ved | Médicaments synthétiques polymères |
Non-Patent Citations (5)
Title |
---|
CHEMICAL ABSTRACTS, vol. 118, no. 24, 14 June 1993 Columbus, Ohio, US; abstract no. 240632, BRUNEEL, D. ET AL: "Polymeric prodrugs of melphalan with increased hydrolytic stability" XP002040095 & PROC. PROGRAM INT. SYMP. CONTROLLED RELEASE BIOACT. MATER., 18TH (1991), 333-4. EDITOR(S): KELLAWAY, IAN W. PUBLISHER: CONTROLLED RELEASE SOC., DEERFIELD, ILL. CODEN: 58GMAH, 1991, * |
J. CONTROLLED RELEASE (1989), 10(1), 17-25 CODEN: JCREEC;ISSN: 0168-3659, 1989, XP002040093 PYTELA, J. ET AL: "Poly(N5-hydroxyalkylglutamines). IV. Enzymic degradation of N5-(2-hydroxyethyl)-L-glutamine homopolymers and copolymers" * |
J. CONTROLLED RELEASE (1994), 31(1), 89-97 CODEN: JCREEC;ISSN: 0168-3659, 1994, XP000456583 MARRE, ANNE DE ET AL: "Evaluation of the hydrolytic and enzymic stability of macromolecular Mitomycin C derivatives" * |
J. CONTROLLED RELEASE (1996), 39(1), 79-92 CODEN: JCREEC;ISSN: 0168-3659, 1996, XP002040091 NICHIFOR, MARIETA ET AL: "Macromolecular prodrugs of 5-fluorouracil. 2: Enzymic degradation" * |
MAKROMOL. CHEM. (1992), 193(12), 3023-30 CODEN: MACEAK;ISSN: 0025-116X, 1992, XP000324000 DE MARRE, ANNE ET AL: "Preparation of 4-nitrophenyl carbonate esters of poly[5N-(2-hydroxyethyl)-L-glutamine] and coupling with bioactive agents" * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7018654B2 (en) | 1999-03-05 | 2006-03-28 | New River Pharmaceuticals Inc. | Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US7005123B1 (en) | 1999-06-17 | 2006-02-28 | Universiteit Gent | Functional poly-α-amino-acid derivatives useful for the modification of biologically active materials and their application |
WO2000078791A3 (fr) * | 1999-06-17 | 2001-12-13 | Univ Gent | DERIVES FONCTIONNELS POLY-α-AMINO ACIDE UTILES POUR LA MODIFICATION DE MATIERES A ACTIVITE BIOLOGIQUE ET APPLICATION DE CES DERIVES |
WO2000078791A2 (fr) * | 1999-06-17 | 2000-12-28 | Universiteit Gent | DERIVES FONCTIONNELS POLY-α-AMINO ACIDE UTILES POUR LA MODIFICATION DE MATIERES A ACTIVITE BIOLOGIQUE ET APPLICATION DE CES DERIVES |
WO2001018548A2 (fr) * | 1999-09-09 | 2001-03-15 | Dade Behring Marburg Gmbh | Groupes protecteurs pour marquage biologique |
WO2001018548A3 (fr) * | 1999-09-09 | 2001-11-22 | Dade Behring Inc | Groupes protecteurs pour marquage biologique |
US6783947B1 (en) | 1999-09-09 | 2004-08-31 | Dade Behring Marburg Gmbh | Protecting groups for biological labeling |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
WO2002034237A1 (fr) * | 2000-08-22 | 2002-05-02 | New River Pharmaceuticals, Inc. | Systemes de liberations d'agents actifs et procedes de protection et d'administration d'agents actifs |
US7427600B2 (en) | 2000-08-22 | 2008-09-23 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
EP2266590A2 (fr) | 2002-02-22 | 2010-12-29 | Shire LLC | Système d'administration de substances actives et méthodes de protection et d'administration de substances actives |
EP1490090A4 (fr) * | 2002-02-22 | 2006-09-20 | New River Pharmaceuticals Inc | Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs |
US7375082B2 (en) | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
EP1490090A2 (fr) * | 2002-02-22 | 2004-12-29 | New River Pharmaceuticals Inc. | Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs |
US7622441B2 (en) | 2002-02-22 | 2009-11-24 | Shire Llc | Sustained release pharmaceutical compounds to prevent abuse of controlled substances |
JP2005524677A (ja) * | 2002-02-22 | 2005-08-18 | ニュー リバー ファーマシューティカルズ インコーポレイテッド | 活性物質送達系及び活性物質を保護し投与する方法 |
EP2266590A3 (fr) * | 2002-02-22 | 2011-04-20 | Shire LLC | Système d'administration de substances actives et méthodes de protection et d'administration de substances actives |
EP2316468A1 (fr) | 2002-02-22 | 2011-05-04 | Shire LLC | Système de distribution et méthodes de protection et d'administration de dextroamphetamine |
EP2316469A1 (fr) | 2002-02-22 | 2011-05-04 | Shire LLC | Système de distribution et méthodes de protection et d'administration de dextroamphetamine |
US7338939B2 (en) | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
US7375083B2 (en) | 2003-09-30 | 2008-05-20 | Shire Llc | Pharmaceutical compositions for prevention of overdose or abuse |
Also Published As
Publication number | Publication date |
---|---|
WO1997036616A3 (fr) | 1997-11-06 |
EP0891191A1 (fr) | 1999-01-20 |
GB9606975D0 (en) | 1996-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5853713A (en) | Biologically compatible linear block copolymers of polyalkylene oxide and peptide units | |
EP0187547B1 (fr) | Médicaments synthétiques polymères | |
EP2052011B1 (fr) | Agent ciblé thérapeutique dendrimère de polylysine | |
US7893023B2 (en) | Prodrugs activated by plasmin and their use in cancer chemotherapy | |
RU2149646C1 (ru) | Полимерный конъюгат, фармацевтическая композиция | |
Subr et al. | Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly [N-(2-hydroxypropyl)-methacrylamide] copolymer drag carriers in vitro and antitumour activity measured in vivo | |
US9289510B2 (en) | Polymeric drug delivery conjugates and methods of making and using thereof | |
Przybylski et al. | Pharmacologically active polymers, 17. Syntheses and characterization of polymeric derivatives of the antitumor agent methotrexate | |
WO2000069472A2 (fr) | Composes de promedicaments anti-tumoraux actives par des enzymes | |
EP0961619A1 (fr) | Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques | |
WO1997036616A2 (fr) | Agent anti-tumoral | |
US20110160147A1 (en) | Novel dual targeting antitumoral conjugates | |
CA2333321A1 (fr) | Complexe medicamenteux | |
Li et al. | A stimuli-responsive Janus peptide dendron–drug conjugate as a safe and nanoscale drug delivery vehicle for breast cancer therapy | |
EP1753776B1 (fr) | Camptothecines conjuguees en position 7 avec des peptides cycliques utilisees comme agents cytostatiques | |
JPH09501674A (ja) | ミトマイシンを組み込む薬配達薬剤 | |
US6376617B1 (en) | Bioactive derivatives of camptothecin | |
JP2004504358A (ja) | 抗腫瘍薬のポリマー複合体 | |
US11319341B2 (en) | Immune-stimulating soluble doxorubicin-conjugated complex | |
De Marre et al. | Synthesis of macromolecular Mitomycin C derivatives | |
Nichifor et al. | Macromolecular prodrugs of 5-fluorouracil. 1: Synthesis and hydrolytic stability | |
Ohya et al. | Synthesis of 6‐O‐carboxymethylchitin immobilizing doxorubicins through tetrapeptide spacer groups and its enzymatic release behavior of doxorubicin in vitro | |
Soyez et al. | Macromolecular derivatives of N, N-di-(2-chloroethyl)-4-phenylenediamine mustard. 1. Synthesis and in vitro hydrolytic stability | |
Pató et al. | Synthesis of New Poly (N-Vinyl Pyrrolidone-Co-Maleic Acid) Peptide Hormone Conjugates with Anticancer Activity | |
Song et al. | Synthesis and antitumor activity of poly (organophosphazene)/doxorubicin conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997915567 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: CA |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP Ref document number: 97535049 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1997915567 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997915567 Country of ref document: EP |